[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postmenopausal-women\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postmenopausal-women":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,53,83,111,146,167,190,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053825","office-hysteroscopy-in-postmenopausal-women-a-randomized-trial-of-cervical-preparation-strategies-100053825",false,"NCT07697781","Office Hysteroscopy in Postmenopausal Women: A Randomized Trial of Cervical Preparation Strategies","A Four-Arm Prospective Randomized Controlled Trial Comparing Oral Misoprostol, Two Vaginal Estrogen Regimens, and No Cervical Preparation Before Office Hysteroscopy in Postmenopausal Women","Inclusion Criteria:\n\n* Women with postmenopausal status.\n* Scheduled for office hysteroscopy for the evaluation of suspected intrauterine pathology.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected hormone-dependent malignancy (e.g., breast or endometrial cancer).\n* Active genital tract infection.\n* Contraindication or known hypersensitivity to misoprostol or vaginal estrogen.\n* Refusal to undergo office hysteroscopy without anesthesia.\n* Active uterine bleeding preventing adequate hysteroscopic visualization on the day of the procedure.","FEMALE",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this randomized controlled trial is to evaluate the effectiveness of different cervical preparation strategies before office hysteroscopy in postmenopausal women undergoing evaluation for intrauterine pathology.\n\nThe main questions to answer are:\n\nDoes cervical preparation improve the success rate of complete office hysteroscopy in postmenopausal women? Which cervical preparation strategy provides better patient tolerance, as assessed by pain intensity during the procedure?\n\nResearchers will compare four cervical preparation protocols (14-day vaginal estrogen, 7-day vaginal estrogen, oral misoprostol, and no cervical preparation) to determine their effects on procedural success, pain, procedure duration, and perioperative complications.\n\nParticipants will be randomly assigned to one of the four cervical preparation protocols. They will undergo office hysteroscopy using a vaginoscopic (\"no touch\") approach without anesthesia. Then, they will have pain assessed using a visual analog scale (VAS) during the procedure. Finally, these informations will be collected: procedural success, procedure duration, bleeding, and perioperative complications.",[25,26,27,28,29],"Postmenopausal Women","Intrauterine Diseases","Endometrial Pathology","Postmenopausal Bleeding","Abnormal Uterine Bleeding (AUB)",[31,32,33,34,35,36,37,38,39],"Postmenopausal women","Postmenopausal bleeding","Office hysteroscopy","Cervical preparation","Vaginal estrogen","Oral misoprostol","Visual Analog Scale","Vaginoscopy","No touch approach","RECRUITING","2026-07-09",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":44},"2026-01-02",{"date":48,"type":19},"2026-08-20",{"name":50,"class":51},"Faculty of Medicine of Tunis","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100642517","balance-fall-risk-and-gait-in-women-with-total-knee-arthroplasty-100642517","NCT07650175","Balance, Fall Risk, and Gait in Women With Total Knee Arthroplasty","Investigation of Balance, Fall Risk, Gait Performance, and Quality of Life in Postmenopausal Women Undergoing Total Knee Arthroplasty","Inclusion Criteria:\n\n* Volunteering to participate in the study.\n* Being 60 years of age or older.\n* Having a Mini Mental Test score of 24 or higher.\n* Not having undergone previous arthroplasty surgery on the knee where surgery is planned.\n* Having experienced unilateral TDA.\n* Being a postmenopausal woman\n\nExclusion Criteria:\n\n* Individuals whose vital signs are unstable after surgery, or who develop any major complications such as deep vein thrombosis, pulmonary embolism, wound infection, or prolonged anesthesia side effects.\n* Presence of any neurological, vestibular, visual, cardiopulmonary, auditory, or cognitive deficits that may affect measurements.\n* Individuals diagnosed with diabetes.",true,"60 Years","85 Years",{"count":64,"type":19},30,"OBSERVATIONAL","Total knee arthroplasty (TKA) is a commonly performed surgical procedure aimed at reducing pain, restoring joint function, and improving quality of life, particularly among older women. Despite improvements in pain and functional outcomes following TKA, findings regarding balance, fall risk, and gait performance remain inconsistent. Impairments in these parameters may adversely affect daily activities, independence, and overall quality of life.\n\nUnlike previous studies that have primarily focused on one or two outcomes, this study will comprehensively evaluate balance, fall risk, gait performance, and quality of life in postmenopausal women who have undergone TKA. The findings are expected to provide a more holistic understanding of long-term functional outcomes following TKA and contribute to the planning of rehabilitation programs. Therefore, the aim of this study is to compare balance, fall risk, gait performance, and quality of life between postmenopausal women who have undergone TKA and healthy postmenopausal women.",[68,25,69,70,71,72],"Total Knee Arthroplasty","Quality of Life (QOL)","Balance","Risk of Falling","Walking","NOT_YET_RECRUITING","2026-06-10",{"date":76,"type":44},"2026-06-16",{"date":78,"type":19},"2026-06-20",{"date":80,"type":19},"2026-07-22",{"name":82,"class":51},"Karabuk University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":20,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":52},"100616218","ai-assisted-relaxation-and-breathing-training-in-postmenopausal-women-100616218","NCT07302750","AI-Assisted Relaxation and Breathing Training in Postmenopausal Women","The Effectiveness of Artificial Intelligence-Assisted Relaxation and Breathing Training on Pain Intensity and Quality of Life in Postmenopausal Women","Inclusion Criteria:\n\n* Women aged 45 to 65 years\n* Being in natural menopause (no menstrual bleeding for at least 12 months)\n* Having non-specific chronic musculoskeletal pain for at least 3 months (reporting a pain intensity of at least 4 cm on the VAS)\n* Using only standard analgesic medications for pain management\n* Being literate\n* Owning a smartphone or tablet, having the ability to listen to audio recordings, and having adequate skills to participate in online sessions\n* Being willing to participate in the study and providing written informed consent\n\nExclusion Criteria:\n\n* Surgical or medication-induced menopause\n* Regular use of opioid analgesics, anticonvulsants, antidepressants, or similar medications\n* Uncontrolled advanced cardiovascular, oncological, metabolic, rheumatologic, or neurological diseases\n* Body Mass Index (BMI) of 40 kg\u002Fm² or higher\n* History of major surgery or severe trauma within the past 3 months","45 Years","65 Years",{"count":93,"type":19},48,[22],"This study aims to evaluate the effectiveness of relaxation and breathing training delivered by a physiotherapist and by an artificial intelligence-assisted system in postmenopausal women with non-specific chronic musculoskeletal pain. Menopause and the postmenopausal period are associated with decreased estrogen levels, structural and functional changes in the musculoskeletal system, increased pain prevalence, reduced muscle function, and impaired quality of life. Relaxation techniques, breathing-focused exercises, and mind-body practices have been shown to reduce pain, improve psychological well-being, and enhance sleep quality. With the growing use of digital health technologies, AI-supported relaxation training may offer personalized guidance, easy accessibility, and sustainable home-based practice, although its effectiveness in postmenopausal women has not yet been demonstrated.\n\nIn this three-arm randomized controlled trial, participants will be assigned to physiotherapist-led relaxation and breathing training, AI-assisted relaxation and breathing training, or a control group. Interventions will last eight weeks and include sessions three days per week, each approximately 30 minutes. The physiotherapist-guided group will perform sessions face-to-face, while the AI-assisted group will complete prerecorded relaxation and breathing exercises created with AI-generated scripts and voice recordings. The control group will continue daily routines without structured training during the study period.\n\nAssessments will be conducted at baseline and at the end of eight weeks. Outcome measures will include pain severity, pressure pain threshold, musculoskeletal symptoms, menopause-specific quality of life, psychological status, sleep quality, dyspnea, and participant satisfaction. The study aims to compare the effects of physiotherapist-led and AI-assisted training modalities on pain, musculoskeletal health, sleep, psychological well-being, and quality of life. Findings are expected to contribute to the development of accessible and cost-effective interventions that support symptom management and improve the daily functioning of postmenopausal women.",[97,25],"Postmenopausal Period",[99,100,101,102],"postmenopausal","artificial intelligence","pain management","quality of life","2026-06-06",{"date":74,"type":44},{"date":106,"type":44},"2026-04-01",{"date":108,"type":19},"2027-02",{"name":110,"class":51},"Baskent University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":60,"sex":16,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":20,"phases":122,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":52},"100589347","acute-impact-of-whey-protein-enriched-milk-fat-globule-membrane-supplementation-on-postprandial-markers-of-heart-and-brain-health-100589347","NCT06953232","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health in Postmenopausal Women Living With Overweight and at Moderate Risk for Cardiovascular Disease.","Inclusion Criteria:\n\n* Apparently healthy postmenopausal women (not menstruating for 12 or more months)\n* Aged 50 - 75 years\n* BMI: 25 - 40 kg\u002Fm²\n* Moderate CVD risk\n* Recreationally active (\\> 3 x 30 min moderate exercise per week)\n* Understands and is willing and able to comply with all study procedures including eating a high-fat breakfast meal\n* Fluent in written and spoken English\n* Access to, and able to use, the internet\u002Fcomputer\u002Ftablet device\n\nExclusion Criteria:\n\n* Smoking (including vaping)\n* Diagnosed with cardiovascular disease or suffered myocardial infarction \u002Fstroke in the past twelve months\n* Existing or significant past medical history of any medical condition likely to affect the study outcomes e.g., diabetes, digestive, cancer or thyroidal disease, neurological disease (Alzheimer's disease, other form of dementia, mild cognitive impairment), or serious mental illness know to affect cognition (schizophrenia, schizoaffective disorder, bipolar disorder), learning disorders (dyslexia)\n* Early or premature menopause resulting from medical conditions or undergoing surgery\n* Hormone replacement therapy within last 6 months\n* Prescribed medications likely to interfere with study outcomes (including lipid\u002Fcholesterol-lowering medications, including statins; blood thinners, antiplatelets (anticoagulants) such as heparin, etc.; medications for blood pressure; inflammation such as nonsteroidal anti-inflammatory drugs, aspirin, etc.; immune function, or lipid\u002Fcarbohydrate metabolism) or prescribed antibiotics within the last three months\n* Use of antidepressant or anti-anxiety medication if it has changed in the last three months or expected to change within the 3-month study period\n* Taking vitamin, mineral, or fatty acid supplements (e.g., fish oil, calcium) or unwilling stop consuming these for the duration of the study (including sufficient washout period)\n* Working night shifts\n* Inaccessible veins for blood collection via cannulation\n* Unstable weight history (≥3 kg loss or gain in the previous 3 months) or planning or currently on a weight reduction scheme\n* Known allergy or intolerance to study food (including lactose intolerance, dairy, and wheat)\n* Being vegan or any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention or metabolic study\n* Excessive alcohol consumption: \\>21 unit\u002Fwk (i.e., more than 10 and a half pints of beer or 21 small glasses of wine)\n* Currently taking part or have participated in another research study in the last two months (e.g., dietary intervention)","50 Years","75 Years",{"count":121,"type":19},16,[22],"In a single-blind, randomised, placebo-controlled crossover manner, this study aims to assess the impact of a high-fat mixed meal containing a whey protein (WP)-enriched milk fat globule membrane (MFGM) powdered ingredient on markers of heart and brain health in the fed state among middle-to-older-aged, postmenopausal women living with overweight and at moderate risk for cardiovascular disease.\n\nParticipants will attend two \\~8 hour study visits, where they will consume a high-fat meal containing a WP-enriched MFGM powdered ingredient or a placebo WP-based powdered ingredient. Each visit will involve anthropometric measurements and periodic assessments of heart health, including blood pressure and blood vessel stiffness measurements, blood sample collections, as well as computer-based tests measuring mood and cognition (brain function) over a 6-hour postprandial period.",[125,126,127,25,128],"Cardiovascular Diseases","Cognition","Overweight or Obesity","Cardiometabolic Risk Factors",[130,131,132,133,134,135,136],"Milk fat globule membrane","Milk polar lipids","triacylglycerol","postprandial","cholesterol","cardiometabolic disease risk","cognitive function","2026-05-18",{"date":139,"type":44},"2026-05-20",{"date":141,"type":44},"2025-09-30",{"date":143,"type":19},"2026-10",{"name":145,"class":51},"Loughborough University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":118,"maxAge":61,"enrollmentInfo":153,"targetDuration":4,"studyType":20,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":52},"100626543","effect-of-electroacupuncture-on-central-obesity-and-fatty-liver-in-postmenopausal-women-100626543","NCT07437001","Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women","Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Their ages will be ranged between 50 and 60 years old.\n2. Their body mass index will be ranged from 30-40 kg\u002Fm2.\n3. SGOT more 40 U\u002FL.\n4. SGPT more 40 U\u002FL.\n5. Waist\u002FHip Ratio more 1 cm.\n6. Triglyceride more 150 mg\u002Fdl.\n7. Cholesterol more 200 mg\u002Fdl.\n8. LDL more 100 mg\u002Fdl.\n9. HDL less 40 mg\u002Fdl.\n\nExclusion Criteria:\n\n1. Cancer.\n2. Concomitant cardiovascular disorders.\n3. Respiratory, renal and liver dysfunction.",{"count":154,"type":19},60,[22],"The aim of this study is to determine the effect of electroacupuncture on central obesity and fatty liver in postmenopausal women.",[25],"2026-02-22",{"date":160,"type":44},"2026-02-27",{"date":162,"type":19},"2026-03-01",{"date":164,"type":19},"2026-06-15",{"name":166,"class":51},"Cairo University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":60,"sex":16,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":20,"phases":177,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100621131","phase-1-a-study-of-single-dose-of-bl0175-in-postmenopausal-women-100621131","NCT07366632","A Study of Single Dose of BL0175 in Postmenopausal Women","A Phase I, International, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of BL0175 Injection Compared With a Single Dose of Fulvestrant Injection in Postmenopausal Women","Inclusion Criteria:\n\n1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and sign informed consent form.\n2. Postmenopausal female participants aged ≥ 18 years old.\n3. Body weight ≥ 45kg and body mass index (BMI= weight\u002Fheight2) scores ≥ 18 kg\u002Fm2 and ≤ 35 kg\u002Fm2.\n4. Participants with laboratory tests, physical examinations, vital signs, and electrocardiogram (ECG) results judged by the investigator as normal or abnormal with no clinical significance (NCS).\n\nExclusion Criteria:\n\n1. Participants with a history or current presence of any cardiovascular, gastrointestinal, endocrine, hematological, hepatic, immunological, metabolic, urinary, pulmonary, neurological, dermatological, psychiatric, renal, and\u002For other major diseases that are considered clinically significant by the investigator.\n2. A history of allergy to fulvestrant, alcohol, castor oil, benzyl alcohol, benzyl benzoate or any other comparable or similar products, or prone to allergic reactions (such as: prone to angioedema, urticaria, asthma, rash, etc.), or history of allergy to two or more drugs (or foods).\n3. Participants with current concomitant sciatica, neuralgia, or peripheral neuropathy.\n4. History of allogeneic transplantation of organs, bone marrow or stem cell.\n5. Active infection, a known history of hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection or screening for infectious disease (HBsAg, hepatitis C virus antibody \\[HCV-Ab\\], or human immunodeficiency virus antigen\u002Fantibody \\[HIV-Ag\u002FAb\\]) during the screening period is positive.\n6. Unable to refrain from or anticipate the use of any prescription medications not for the treatment of concomitant diseases within 4 weeks prior to administration, or any over-the-counter drugs (including but not limited to Chinese herbal medicines, compound preparations of Chinese herbal medicines, health products, etc.) not for the treatment of concomitant diseases within 2 weeks prior to administration.\n7. Participants who are vaccinated within 14 days prior to dosing administration.\n8. Those who donated plasma or blood within 12 weeks prior to the dosing administration or donated or lost blood 400 mL or more within 12 weeks prior to the dosing administration, or plan to donate during the study.\n9. Any history of coagulation dysfunction, bleeding diathesis (e.g., disseminated intravascular coagulation, coagulation factor deficiencies), long-term anticoagulant therapy (excluding antiplatelet therapy and low-dose warfarin), active bleeding (such as gastrointestinal bleeding), or clinically significant thrombocytopenia.\n10. Intolerance to \u002F fear of venipuncture, needles, or blood collection difficulties (such as poor vascular conditions, fear of blood collection, needle dizziness, etc.).\n11. Those who underwent major surgery within 4 weeks before screening, or plan to undergo major surgery during the study.\n12. Those who have taken\u002Fused investigational drugs, vaccines or devices within the 4 weeks or 5 half-lives of investigational drug (whichever is longer) prior to the dosing administration.\n13. Participants who with a history of alcoholism, or with a history of alcohol abuse within 3 months prior to screening (by self-declaration) \\> 14 alcohol units per week (1 alcohol unit is about equal to 50° white wine 35 mL or 5° beer 350 mL or wine 150 mL). Participants are unable\u002Funwilling to refrain from alcohol, or strenuous exercise 48 hours prior to each study visit.\n14. Participants who with a history of drug abuse or drug dependence, or those who have used illicit drugs within 1 year prior to screening.\n15. Positive alcohol or drug screen results at Baseline.\n16. Those who are determined by the investigator to be ineligible for other reasons.","18 Years",{"count":176,"type":19},27,[178],"PHASE1","The goal of this clinical trial is to learn the safety and PK of the single dose of BL0175 Injection in postmenopausal women and to compare that with a single dose of Fulvestrant Injection. The main questions it aims to answer are:\n\n* What medical problems do participants have when using drug BL0175?\n* How long can BL0175 remain in your blood? Participants will receive a single dose of drug BL0175 or a single dose of Fulvestrant Injection in a randomized method",[25],"2026-01-16",{"date":183,"type":44},"2026-01-26",{"date":183,"type":19},{"date":186,"type":19},"2026-12-21",{"name":188,"class":189},"Shanghai Best-Link Bioscience, LLC","INDUSTRY",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":20,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100607317","the-effectiveness-of-combined-pelvic-floor-muscle-training-and-vaginal-oestrogen-therapy-in-postmenopausal-women-with-stress-urinary-incontinence-100607317","NCT07186985","The Effectiveness of Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy in Postmenopausal Women With Stress Urinary Incontinence","Inclusion Criteria:\n\n* Patients diagnosed with stress urinary incontinence.\n* Women who have been naturally postmenopausal for at least 1 year or are postmenopausal due to bilateral oophorectomy (surgical removal of both ovaries).\n* Have had sexual intercourse to ensure feasibility of urogenital tract examination and assessment.\n* Patients who consent to participate in the study and comply with the treatment protocol, including performing pelvic floor muscle training (PFMT) and completing topical vaginal estrogen therapy.\n\nExclusion Criteria:\n\n* Patients with concomitant neurological disorders, urinary tract infections, prior pelvic radiotherapy, or congenital malformations of the lower urinary tract.\n* Genitourinary malformations or fistulas causing continuous urinary incontinence.\n* Genitourinary cancers or tumors of the urinary tract.\n* History of spinal cord injury or central nervous system injury affecting the centers that control urination.\n* Patients previously treated for stress urinary incontinence (SUI) (surgery, medications, exercises).\n* Patients with severe heart disease, coronary artery disease, or myocardial ischemia.\n* Patients with pelvic organ prolapse stage III or higher, unexplained vaginal bleeding, confirmed or suspected breast cancer, or vaginitis.\n* Presence of premalignant factors or suspected steroid-dependent cancers such as endometrial carcinoma.\n* History of or current hepatic tumors, or progressive liver or biliary disease.\n* Coagulation\u002Fthrombotic disorders, or a history of thromboembolism or stroke.\n* Severe hypertriglyceridemia.\n* Hypersensitivity to any component of vaginally administered estrogen products.\n* The patient or family members are unable to use a smartphone (Android or iOS) to participate in the monitoring program.\n* The patient does not agree to participate in the study.",{"count":197,"type":19},115,[22],"The objective of this clinical trial is to investigate whether the combination of pelvic floor muscle training (PFMT) and topical estrogen is more effective in treating stress urinary incontinence (SUI) in postmenopausal women compared to topical estrogen alone. The trial will also analyze factors related to the outcomes of the combined therapy. The key questions this trial aims to answer are:\n\n* Does the combination of PFMT and topical estrogen improve symptoms of stress urinary incontinence in postmenopausal women better than topical estrogen alone?\n* Which factors are associated with the effectiveness of the combined therapy?\n\nResearchers will compare the group receiving the combined therapy (pelvic floor muscle training plus topical estrogen) with the group receiving topical estrogen alone to determine whether adding PFMT to estrogen therapy provides additional treatment benefits for SUI in postmenopausal women.\n\nParticipants will:\n\n\\- Be randomly assigned to one of two groups:\n\nGroup 1: Undergo a pelvic floor muscle training (PFMT) program combined with topical estrogen therapy (e.g., vaginal cream\u002Fapplication,...).\n\nGroup 2: Receive topical estrogen therapy alone (e.g., vaginal cream\u002Fapplication,...).\n\n* Follow the assigned intervention protocol for a specified duration.\n* Attend regular clinic visits for clinical examinations, assessment of incontinence severity, and related measurements.\n* Monitor and record their incontinence symptoms and the frequency of urine leakage during daily activities.",[201,25],"Stress Urinary Incontinence (SUI)",[203,204,205,206,207],"stress urinary incontinence (SUI)","postmenopausal women","Pelvic Floor Muscle Training","Vaginal Oestrogen","Pelvic floor rehabilitation","2025-09-18",{"date":210,"type":44},"2025-09-22",{"date":212,"type":19},"2025-11-01",{"date":214,"type":19},"2027-02-28",{"name":216,"class":51},"Hanoi Medical University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":60,"sex":16,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":229,"studyType":65,"phases":4,"briefSummary":230,"conditions":231,"keywords":234,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":52},"100495134","screening-triage-and-risk-stratification-100495134","NCT05727228","Screening Triage and Risk Stratification","Improving Screening Triage in Older Postmenopausal HPV-screen-positive Women Aged 50-64 and Risk-stratification of Women Aged 23-64 After Excision","I-share","Inclusion Criteria:\n\n* HPV-screen-positive (aged 50-64)\n* Women who undergo test-of-cure (i.e. HPV and cytology) six months after LEEP in Central Denmark Region (aged 23-64)\n* Women who undergo follow-up test (i.e. HPV and cytology) 12 months after LEEP\n* A valid cytology-triage result (aged 23-64)\n\nExclusion Criteria:\n\n* Listed in the registry as a person who have rejected to participate in research\n* Invalid cytology and HPV result six months after LEEP\n* No residual material available","23 Years","64 Years",{"count":228,"type":19},5000,"5 Years","* To investigate the performance of cytology, extended genotyping, p16\u002FKi67 dual stain cytology, DNA methylation and viral load as triage markers in post-menopausal HPV-screen-positive women aged 50-64 years in the organized screening program to predict the risk of developing CIN2+. (work package 1)\n* To investigate the performance of cytology, extended genotyping, p16\u002FKi67 dual stain cytology, DNA methylation and viral load six months after cervical excision to predict the long-term risk of residual\u002Frecurrent CIN2+ lesions among women aged 23-64 (work-package 2)",[232,233,25],"Cervix Cancer","HPV Testing",[235,236],"mass screening","triage biomarkers","2023-02-03",{"date":239,"type":44},"2023-02-14",{"date":241,"type":19},"2023-02-27",{"date":108,"type":19},{"name":244,"class":51},"University of Aarhus"]